The Endpoints 100 survey: CEOs changed the way biotechs operate during the pandemic. Things will never be the same again
With the US at the front of the line for new Covid-19 vaccines, the biotech industry is looking at the near-term end of the pandemic — or at least a more manageable easing of the rules established during the lockdown. But only a relative handful of CEOs expect things to return to the way they were in a pre-pandemic era. Most are planning to go forward with a whole new set of guidelines for staffers — and flexibility lies at the heart of what’s ahead as people are cleared to go back to the office.
We surveyed our group of Endpoints 100 executives, mostly CEOs, to take the industry’s pulse. This was the latest in close to 5 years of surveys. And several common themes were clear.
First, after a rip-roaring spin on Wall Street as a wave of new IPOs delivered fresh billions to drug hunters, there’s a record level of excitement about asset valuations and access to capital. The vast majority are expanding this year with new hires. And a remarkable 88% of the 82 executives who took the survey say they won’t be returning to the business-as-usual style they were accustomed to in a pre-pandemic world.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.